^
CANCER:

Childhood B Acute Lymphoblastic Leukemia





Show legend
Group by Gene:
Include preclinical:

0
CD19-targeted CAR-T immunotherapy
tisagenlecleucel-T
1
Proteasome inhibitor
bortezomib
2
Multi-tyrosine kinase inhibitor
nintedanib
3
Proteasome inhibitor, CD20 inhibitor
rituximab + bortezomib
4
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
5
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib
6
CD19 inhibitor, CD3 agonist
blinatumomab
7
THF dehydrogenase inhibitor, Alkylating agent, Tubulin polymerization inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter, Immunomodulator, Thymidylate synthase inhibitor
cytarabine + cyclophosphamide oral + vincristine + methotrexate + pegaspargase
8
Topoisomerase II inhibitor, GCR agonist, Tubulin polymerization inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
vincristine + dexamethasone + mitoxantrone + pegaspargase
9
Topoisomerase II inhibitor, Alkylating agent, DNA inhibitor, DNA synthesis inhibitor, Immunomodulator
cyclophosphamide oral + etoposide oral + nelarabine
cyclophosphamide oral + etoposide oral + clofarabine
10
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib
11
Steroid receptor agonist
prednisone
12
Alkylating agent, Immunomodulator
cyclophosphamide oral
13
CD9 inhibitor
AT1412
14
AKT inhibitor
MK-2206
15
HER2 inhibitor
trastuzumab
16
SYK inhibitor
GS-9973
17
Menin-MLL inhibitor
DS-M1
No biomarker
EPOR rearrangement
ABL1 fusion
JAK2 fusion
PDGFRB fusion
PDGFRA fusion
ABL2 fusion
FGFR fusion
IL7R mutation
SH2B3 alteration
CRLF2 rearrangement + JAK2 fusion
CD20 expression
PAX5 fusion
HER-2 expression
SNX2-ABL1 fusion
MLL rearrangement
CD9 expression
FOXO1 underexpression
IGH-CRLF2 fusion + JAK2 R867Q
JAK1 S646F
IGH-CRLF2 fusion
IGH-CRLF2 fusion + JAK2 GPInsR683
P2RY8-CRLF2 fusion + JAK2 QGinsR683
EBF1-PDGFRB fusion
KRAS mutation
KMT2A rearrangement
NRAS mutation